Humacyte

Humacyte Develops Products for Vascular Disease and Anatomical Catheter Replacement. It is developing a disruptive biotechnology platform to provide universally implantable bioengineered human tissues and organs, aiming to improve patients' lives and transform medical practice. The company develops and manufactures acellular tissues for the treatment of various diseases, injuries, and chronic conditions. Humacyte’s initial opportunity lies in the portfolio of Human Acellular Vessels (HAV), which are currently in late-stage clinical trials for multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral artery disease.